Pembrolizumab: all 1,753 studies that test it

Page 18 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the EyeCompletedNCT02697630Phase 2
• A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative SurgeryTerminatedNCT02691026Phase 2
• Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)CompletedNCT02684292Phase 3
• Clinical Study of CMP-001 in Combination With Pembrolizumab or as a MonotherapyCompletedNCT02680184Phase 1
• Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular LymphomaCompletedNCT02677155Phase 2
• Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic MelanomaCompletedNCT02676869Phase 1
• CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)Status unknownNCT02675946Phase 1
• Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT02665650Phase 1
• A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)WithdrawnNCT02663258Phase 2
• A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsWithdrawnNCT02661100Phase 1/2
• Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator PhenotypeActive, not recruitingNCT02658279Not applicable
• Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT02644369Phase 2
• Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseCompletedNCT02636010Phase 2
• Phase I Dose Escalation Study for VIP152 in Patients With Advanced CancerCompletedNCT02635672Phase 1
• Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or NivolumabCompletedNCT02628574Phase 1
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
• Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)TerminatedNCT02625961Phase 2
• Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaCompletedNCT02620423Phase 1
• Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic MelanomaActive, not recruitingNCT02617849Phase 2
• Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid TumorsActive, not recruitingNCT02608385Phase 1
• A Study of Pembrolizumab for Patients With Thymic Epithelial TumorCompletedNCT02607631Phase 2
• Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerActive, not recruitingNCT02600949Phase 1
• A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC PatientsCompletedNCT02599779Phase 2
• MRI and PET to Assess Pembrolizumab ResponseTerminatedNCT02591654Early Phase 1
• Trial of Chemoradiation and Pembrolizumab in Patients With Rectal CancerWithdrawnNCT02586610Phase 2
• Pembrolizumab in Untreated Extensive SCLCCompletedNCT02580994Phase 2
• GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsCompletedNCT02575404Phase 1
• Pilot Study of Vigil™ + Pembrolizumab for Advanced MelanomaCompletedNCT02574533Phase 1
• Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)CompletedNCT02565992Phase 1
• Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)TerminatedNCT02564380Phase 2
• Pembrolizumab in Muscle Invasive/Metastatic Bladder CancerActive, not recruitingNCT02560636Phase 1
• Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced CancerCompletedNCT02546531Phase 1
• Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed GlioblastomaTerminatedNCT02530502Phase 1
• A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid TumoursActive, not recruitingNCT02521844Phase 1
• Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyActive, not recruitingNCT02432963Phase 1
• Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinActive, not recruitingNCT02414269Phase 1/2
• Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaActive, not recruitingNCT02359565Phase 1
• Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)TerminatedNCT02346955Phase 1
• Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2bCompletedNCT02339324Phase 1
• Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung CancerCompletedNCT02318771Phase 1
• Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic CancerStatus unknownNCT02305186Phase 1/2
• Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475CompletedNCT02303366Phase 1
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
• Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMActive, not recruitingNCT02287428Phase 1
• Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI CancersTerminatedNCT02268825Phase 1
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
• Treatment of Advanced Melanoma With MK-3475 and PeginterferonCompletedNCT02112032Phase 1
• CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)CompletedNCT02043665Phase 1
• Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)CompletedNCT02014636Phase 1
• A Study of DKN-01 in Combination With Paclitaxel or PembrolizumabCompletedNCT02013154Phase 1
• LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabCompletedNCT01986426Phase 1
• 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAINActive, not recruitingNCT01822652Phase 1
• Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast CancerCompletedNCT01676753Phase 1

← Pembrolizumab overview